PENPenumbra Inc
Surgical & Medical Instruments & Apparatus
- Revenue
- $1.4B
- 17% YoY
- Operating margin
- 13.5%
- 1636% YoY
- EBITDA
- $207M
- 527% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear134% of net incomeCash flow under 80% of net income
- Dilutive SBCClear4% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear8% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $748M | $847M | $1.1B | $1.2B | $1.4B | 17% |
| Operating income | −$8M | $6M | $74M | $9M | $189M | 1940% |
| Net income | $5M | −$2M | $91M | $14M | $178M | 1168% |
| Operating cash flow | $10M | −$56M | $97M | $168M | $239M | 42% |
| Capex | $21M | $19M | $15M | $21M | $64M | 201% |
| Stock-based comp | $66M | $37M | $51M | $46M | $59M | 28% |
| Buybacks | — | $0 | $0 | $100M | $0 | 100% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $852K | $852K | 178 | 78 |
| FY2024 | $630K | $630K | 136 | 78 |
| FY2023 | $602K | $602K | 144 | 74 |
| FY2022 | $602K | $602K | 127 | 79 |
| FY2021 | $498K | $498K | 164 | 103 |